Lokelma is a drug owned by Astrazeneca and was first authorized for market use on 18 May, 2018. The active ingredient in Lokelma is sodium zirconium cyclosilicate. The drug holds a total of 14 patents, none of which have expired as of now.
Although patent challenges against Lokelma can be filed from May 18, 2022, the generic version of Lokelma will likely be available after October 14, 2035. Notably, the last patent of Lokelma 'Extended use zirconium silicate compositions and methods of use thereof' is set to expire on October 14, 2035. Therefore, the Lokelma generic will likely be released after this date.
Lokelma is typically used in the treatment of hyperkalemia in adults. It works effectively by leveraging its active ingredient, sodium zirconium cyclosilicate, which plays a crucial role in the management and treatment of this condition.
Lokelma has a total of 14 active patents. The patent with the longest validity 'Extended use zirconium silicate compositions and methods of use thereof' is due to expire on October 14, 2035, which will likely influence the release date of Lokelma's generic version. Below is the detail of the patent: